

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2020 OF THE CONDITION AND AFFAIRS OF THE

Maine Community Health Options

NAIC Group		ompany Code1	5077 Employer's ID	Number <u>45-3416923</u>		
Organized under the Laws of	(Current) (Prior) Maine	, State of	Domicile or Port of Entr	уМЕ		
Country of Domicile	Ur	nited States of Ame	rica			
Licensed as business type:	L	ife, Accident & Hea	lth			
Is HMO Federally Qualified? Yes [] No [X]					
Incorporated/Organized	09/26/2011	Con	nmenced Business	01/01/2014		
· <u> </u>	150 Mill Street, Suite 3			Lewiston, ME, US 04240		
otatulory Home office	(Street and Number)		(City or 1	rown, State, Country and Zip Code)		
Main Administrative Office	1	50 Mill Street, Suite	3			
Lewis	ston, ME, US 04240	(Street and Numbe	r)			
	State, Country and Zip Code)		(Are	ea Code) (Telephone Number)		
Mail Address	PO Box 1121		Le	ewiston, ME, US 04243-1121		
(:	Street and Number or P.O. Box)		(City or 1	own, State, Country and Zip Code)		
Primary Location of Books and Recor		150 Mill Street, Suit				
Lewis	ton, ME, US 04240	(Street and Numbe	r) 			
(City or Town,	State, Country and Zip Code)		(Are	ea Code) (Telephone Number)		
Internet Website Address	V	www.healthoptions.c	org			
Statutory Statement Contact	Joanne Lauterbach		. ,	207-330-2390		
jlauterba	(Name) ich@healthoptions.org	,		(Area Code) (Telephone Number) 207-402-3318		
-	E-mail Address)			(FAX Number)		
		OFFICERS				
Chief Executive Officer			Information Officer			
Chief Operating Officer	Robert J Hillman	Chi	ef Financial Officer	Joanne Lauterbach #		
Margaret Kelley, Chief Cli	nical Officer	OTHER				
wargaret Keney, Offici Off						
Rebecca Conrac		CTORS OR TRU Fred Craigie Dr.		Judiann Ferretti Smith		
Sarah Hines Robert Lorenzo)	Holly Korda Heidi Lukas		Asher Kramer # Rocell Marcellino		
Jeff Norris David Shultz		Sharon Reishus Mitchell Stein		David Shipman Lisa Tapert		
Ronnie Westor	1	Douglas Wilson		Lisa Tapert		
	Maine SS:					
all of the herein described assets we statement, together with related exhib condition and affairs of the said report in accordance with the NAIC Annual rules or regulations require differenrespectively. Furthermore, the scope	re the absolute property of the said repo- its, schedules and explanations therein or- ing entity as of the reporting period states Statement Instructions and Accounting P ces in reporting not related to accounti- of this attestation by the described office	orting entity, free an ontained, annexed of above, and of its in ractices and Proceeding practices and pers also includes the	d clear from any liens of or referred to, is a full an necome and deductions dures manual except to procedures, according to erelated corresponding	ting entity, and that on the reporting period stated above, or claims thereon, except as herein stated, and that this d true statement of all the assets and liabilities and of the herefrom for the period ended, and have been completed the extent that: (1) state law may differ; or, (2) that state o the best of their information, knowledge and belief, electronic filing with the NAIC, when required, that is an per requested by various regulators in lieu of or in addition		
Kevin Lewis Chief Executive Officer		Joanne Lauterbach Chief Financial Offic				
Subscribed and sworn to before me the day of	nis		Is this an original filing? If no, 1. State the amendment 2. Date filed			

3. Number of pages attached.....

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	68,950,865		68,950,865	51,384,628
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	0
	2.2 Common stocks			0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$				
	encumbrances)			0	0
5.	Cash (\$62,096,089 , Schedule E - Part 1), cash equivalents				
	(\$77,646,032 , Schedule E - Part 2) and short-term				
	investments (\$, Schedule DA)	139,742,121		139,742,121	114,075,281
6.	Contract loans, (including \$ premium notes)			0	0
7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)	206,500	206,500		
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)	208,899,486	206,500	208,692,986	165,459,909
13.	Title plants less \$ charged off (for Title insurers				
	only)				
14.	Investment income due and accrued	468,996		468,996	357,220
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	2,203,501	1,414,199	789,302	1,386,636
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$			0	0
16.	Reinsurance:	0.000.400		0.000.400	10 100 401
	16.1 Amounts recoverable from reinsurers				
	16.2 Funds held by or deposited with reinsured companies				
17	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon				
	Net deferred tax asset				
19.	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software				
20.	Furniture and equipment, including health care delivery assets	101,499	101,499	0	
۷۱.	(\$	ያርሉ ወለኑ	AVO AVO	n	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$				
25.	Aggregate write-ins for other than invested assets			0	
26.	Total assets excluding Separate Accounts, Segregated Accounts and				
	Protected Cell Accounts (Lines 12 to 25)	222,760,363	3,784,956	218,975,407	182,400,876
27.	From Separate Accounts, Segregated Accounts and Protected Cell			0	0
28.	Accounts	222,760,363	3,784,956	218,975,407	
۷۵.	DETAILS OF WRITE-INS	222,100,000	0,704,930	210,070,407	102,700,070
1101					
1101. 1102.					
1102. 1103.					
1103.	Summary of remaining write-ins for Line 11 from overflow page			0	0
1198.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0			
	Prepaid Expenses		_	_	0
				0	
2502.	Miscellaneous Receivables	,	20,570		
	Security Deposits		12,803	0	
2598.	Summary of remaining write-ins for Line 25 from overflow page			0	
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	1,352,662	1,352,662	0	0

LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, SAI		Current Year		Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1	Claims unpaid (less \$4,251,258 reinsurance ceded)	1	Uncovered		
1.	Accrued medical incentive pool and bonus amounts				
2.	Unpaid claims adjustment expenses				
3. 4.		1,010,372		1,010,372	1,732,073
4.	Aggregate health policy reserves, including the liability of \$9,413,629 for medical loss ratio rebate per the Public				
	•	47 000 050		47 000 050	61 044 000
_	Health Service Act				
5.	Aggregate life policy reserves.				0
6.	Property/casualty unearned premium reserves.				
7.	Aggregate health claim reserves				
8.	Premiums received in advance				
9.	General expenses due or accrued	5,245,371		5,245,371	5,548,788
10.1	Current federal and foreign income tax payable and interest thereon				
	(including \$ on realized capital gains (losses))				0
10.2	Net deferred tax liability				0
11.	Ceded reinsurance premiums payable	974,064		974,064	360,887
12.	Amounts withheld or retained for the account of others	3,263		3,263	320,961
13.	Remittances and items not allocated			0	0
14.	Borrowed money (including \$133,626 current) and				
	interest thereon \$ (including				
	\$ current)	324,702		324,702	450,565
15.	Amounts due to parent, subsidiaries and affiliates				0
16.	Derivatives				0
17.	Payable for securities				0
18.	Payable for securities lending				0
					0
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$				
	reinsurers and \$0 certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$				
	companies				0
21.	Net adjustments in assets and liabilities due to foreign exchange rates				0
22.	Liability for amounts held under uninsured plans			0	0
23.	Aggregate write-ins for other liabilities (including \$				
	current)	46,499	0	46,499	79 , 439
24.	Total liabilities (Lines 1 to 23)	78,835,404	0	78,835,404	98,211,955
25.	Aggregate write-ins for special surplus funds	XXX	XXX	0	2,256,974
26.	Common capital stock				
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				
29.	Surplus notes.				
30.	Aggregate write-ins for other than special surplus funds				0
	Unassigned funds (surplus)			7 922 970	(50,384,177)
31.				7,023,079	(30,364,177)
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		
	32.2 shares preferred (value included in Line 27				
	\$				
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	140,140,003	84, 188, 921
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	218,975,407	182,400,876
	DETAILS OF WRITE-INS				
2301.	Risk Adjustment User Fee Payable	46,499		46,499	79,439
2302.					
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page				
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	40,400	0	46,499	79,439
2501.				,	2,256,974
2502.					
2503.					
2598.	, ,				0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	2,256,974
3001.					
3002.		xxx	xxx		
3003.		xxx	xxx		
3098.	Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
		1	XXX	0	

STATEMENT OF REVENUE AND EXPENSES

	<u> </u>	Current	Year	Prior Year
		1	2	3
		Uncovered	Total	Total
1.	Member Months.	XXX	337,405	468,819
_	Not assessing in a second (including 0	VVV	104 005 000	040 046 000
2.	Net premium income (including \$ non-health premium income)			
3.	Change in unearned premium reserves and reserve for rate credits			
4.	Fee-for-service (net of \$ medical expenses)			0
5.	Risk revenue			
6.	Aggregate write-ins for other health care related revenues	XXX	331,435	298,281
7.	Aggregate write-ins for other non-health revenues			0
8.	Total revenues (Lines 2 to 7)	XXX	243,934,497	242,544,604
	Hospital and Medical:			
9.	Hospital/medical benefits			
10.	Other professional services			7,890,841
11.	Outside referrals		61,749	41,100
12.	Emergency room and out-of-area		32,582,429	40,477,719
13.	Prescription drugs		27,839,971	31,370,404
14.	Aggregate write-ins for other hospital and medical.	0	0	0
15.	Incentive pool, withhold adjustments and bonus amounts		616,469	141, 192
16.	Subtotal (Lines 9 to 15)	0	166,416,012	201,515,678
	Less:			
17.	Net reinsurance recoveries		29,041,649	43,468,638
18.	Total hospital and medical (Lines 16 minus 17)	0	137,374,363	158,047,040
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including \$9,736,315 cost containment expenses		14,204,753	17,303,461
21.	General administrative expenses			37,578,208
22.	Increase in reserves for life and accident and health contracts (including \$			
	increase in reserves for life only)		(4 022 760)	6 300 000
22	Total underwriting deductions (Lines 18 through 22)			
23.				
24.	Net underwriting gain or (loss) (Lines 8 minus 23)			23,315,895
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26.	Net realized capital gains (losses) less capital gains tax of \$			
27.		0	1,574,472	3,276,791
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$		(684, 162)	(1,405,842)
29.	Aggregate write-ins for other income or expenses	0	0	0
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	VVV	56 502 466	25 , 186 , 844
24				, ,
31.	Federal and foreign income taxes incurred			05 400 044
32.	Net income (loss) (Lines 30 minus 31)	XXX	56,502,466	25,186,844
	DETAILS OF WRITE-INS			
0601.	User Fee Revenue - Contraceptive Claims			298,281
0602.				
0603				
0698.	Summary of remaining write-ins for Line 6 from overflow page			0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	331,435	298,281
0701.				
0702.				
0703				
0798.	Summary of remaining write-ins for Line 7 from overflow page		0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX		0
1401.				
1402.				
1403.	Cummany of romaining write ine far Line 14 from everflow page			
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)			0
2901.				
2902.				
2903	Summary of remaining write-ins for Line 29 from overflow page		0	^
2998. 2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	0	0
∠333.	Totalo (Elitos 2001 tilla 2000 pius 2000)(Elite 20 above)	<u> </u>	0	0]

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
		Guilent Teal	i iloi 16ai
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	84,188,921	57,333,556
34.	Net income or (loss) from Line 32	56,502,466	25,186,844
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets	(551,384)	1,668,521
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles.		
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus	0	
48.	Net change in capital and surplus (Lines 34 to 47)	55,951,082	26,855,365
49.	Capital and surplus end of reporting period (Line 33 plus 48)	140,140,003	84,188,921
	DETAILS OF WRITE-INS		
4701.			
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

	CASITILOW	1	2
		Current Year	Prior Year
	Cash from Operations	Ourient real	Thorreal
1.	Premiums collected net of reinsurance	232,399,575	242,880,217
2.	Net investment income		3,214,240
3.	Miscellaneous income		298,281
4.	Total (Lines 1 through 3)	,	246,392,738
5.	Benefit and loss related payments		191,931,736
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)		0
10.	Total (Lines 5 through 9)	-	245,593,694
11.	Net cash from operations (Line 4 minus Line 10)		799,044
11.	Net Cash Horn Operations (Line 4 minus Line 10)	42,999,010	733,044
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
12.	12.1 Bonds	21 151 252	12 000 000
	12.2 Stocks		0
			0
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		0
	12.7 Miscellaneous proceeds		10,000,000
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	21,1/3,6/2	13,000,000
13.	Cost of investments acquired (long-term only):	20.047.004	
	13.1 Bonds		
	13.2 Stocks		0
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		0
	13.6 Miscellaneous applications		0
	13.7 Total investments acquired (Lines 13.1 to 13.6)		0
14.	Net increase (decrease) in contract loans and premium notes		0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(17,444,229)	13,000,000
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		0
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		(208,406)
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders	0	0
	16.6 Other cash provided (applied)	237,914	3,256,955
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	112,051	3,048,549
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	25,666,840	16,847,593
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	114,075,281	97,227,688
	19.2 End of year (Line 18 plus Line 19.1)	139,742,121	114,075,281

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

			***************************************	· • • = · · ·	*********		••• = •••				
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
1.	Net premium income	184,865,202	184,865,202	Supplement	Offity	Offity	Deficitio Fian	Medicare	Medicald	Other rieditii	Non-Health
	Change in unearned premium reserves and reserve for	104,000,202	104,000,202								
	rate credit	58,737,860	58,737,860								
3.	Fee-for-service (net of \$										
	medical expenses)	0									XXX
4.	Risk revenue	0									XXX
5.	Aggregate write-ins for other health care related revenues	331,435	0	0	0		0	0	0	331,435	xxx
6.	Aggregate write-ins for other non-health care related revenues	0	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	0
7.	Total revenues (Lines 1 to 6)	243,934,497	243,603,062	0	0		0	0	0	331,435	0
8.	Hospital/medical benefits	100,796,108	100,796,108								XXX
9.	Other professional services	4,519,286	4,519,286				. [XXX
10.	Outside referrals	61,749	61,749								XXX
11.	Emergency room and out-of-area	32,582,429	32,582,429								XXX
12.	Prescription drugs	27,839,971	27,839,971								XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0		0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	616,469	616,469								XXX
15.	Subtotal (Lines 8 to 14)	166,416,012	166,416,012	0	0	(0	0	0	0	XXX
16.	Net reinsurance recoveries		29,041,649								XXX
17.	Total medical and hospital (Lines 15 minus 16)	137,374,363	137,374,363	0	0	(0	0	0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	Claims adjustment expenses including										
	\$9,736,315 cost containment expenses	14,204,753	14,204,753								
20.	General administrative expenses	40,765,985	40,765,985								
21.	Increase in reserves for accident and health contracts	(4,022,760)	(4,022,760)								XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	188,322,341	188,322,341	0	0			0		0	0
	Total underwriting gain or (loss) (Line 7 minus Line 23)	55,612,156	55,280,721	0	0	(0	0	0	331.435	0
	DETAILS OF WRITE-INS	00,012,100	00,200,721	· ·	•	,	v v	· ·	•	001,100	
0501	User Fee Revenue - Contraceptive Claims	331,435								331,435	XXX
0501.											XXX
0502.			***************************************							· · · · · · · · · · · · · · · · · · ·	XXX
	Summary of remaining write-ins for Line 5 from overflow										
0390.	page	0	0	0	0		0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	331.435	0	0	0	(0	0	0	331.435	XXX
0601.	Totals (Lines 0501 till 0505 plus 0596) (Line 5 above)	001,100	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX XXX	///\
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	T ^{**}										
3030.	page	0	XXX	XXX	XXX	xxx	XXX	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.			 			+					XXX
1302.			ļ								XXX
1303. 1398.	Summary of remaining write-ins for Line 13 from		 							-	XXX
	overflow page	0	0	0	0		0 0	0	0	0	XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0		0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

FART 1 - FREMIONIS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)	200,040,163		15, 174, 961	184,865,202
2. Medicare Supplement				0
3. Dental only				0
4. Vision only				0
5. Federal Employees Health Benefits Plan	0			0
6. Title XVIII - Medicare	0			0
7. Title XIX - Medicaid	0			0
8. Other health				0
9. Health subtotal (Lines 1 through 8)	200,040,163	0	15, 174, 961	184,865,202
10. Life	0			0
11. Property/casualty	0			0
12. Totals (Lines 9 to 11)	200,040,163	0	15,174,961	184,865,202

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

				PARIZ-CLAI	IMS INCURRED DU	KING THE TEAK					
		1	2	3	4	5	6 Federal	7	8	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1.	Payments during the year:		,	''	,	,					
	1.1 Direct	167,728,283	167,728,283								
	1.2 Reinsurance assumed	0	, , .								
	1.3 Reinsurance ceded	32,891,355	32,891,355								
	1.4 Net	134,836,928	134,836,928	0	0	0	0	0	0	0	0
2.	Paid medical incentive pools and bonuses	141,192	141,192								
	Claim liability December 31, current year from Part 2A:	,	,								
٥.	3.1 Direct	23,093,890	23,093,890	0	0	0	0	0	0	0	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	3.3 Reinsurance ceded	4,251,258	4,251,258	0	0	0	0	0	0	0	0
	3.4 Net	18,842,632	18,842,632	0	0	0	0	0	0	0	0
4	Claim reserve December 31, current year from Part 2D:					······					
••	4.1 Direct	0									
	4.2 Reinsurance assumed	0									
	4.3 Reinsurance ceded	0									
	4.4 Net	0	0	0	0	0	0	0	0	0	0
5.	Accrued medical incentive pools and bonuses, current										
0.	year	616.469	616,469								
6	Net healthcare receivables (a)	(18,440)	(18,440)								
	Amounts recoverable from reinsurers December 31,										
	current year	6,026,439	6,026,439								
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	25,041,070	25,041,070	0	0	0	0	0	0	0	0
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	8.3 Reinsurance ceded	1,944,942	1,944,942	0	0	0	0	0	0	0	0
	8.4 Net	23,096,128	23,096,128	0	0	0	0	0	0	0	0
9.	Claim reserve December 31, prior year from Part 2D:		, ,								
	9.1 Direct	0									
	9.2 Reinsurance assumed	0									
	9.3 Reinsurance ceded	0									
	9.4 Net	0	0	0	0	0	0	0	0	0	0
10.	Accrued medical incentive pools and bonuses, prior year	141, 192	141,192								
11.	Amounts recoverable from reinsurers December 31,	, -	, -								
	prior year	12,182,461	12,182,461								
12.	Incurred Benefits:										
	12.1 Direct	165,799,543	165,799,543	0	0	0	0	0	0	0	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	29,041,649	29,041,649	0	0	0	0	0	0	0	0
	12.4 Net	136,757,894	136,757,894	0	0	0	0	0	0	0	0
13	Incurred medical incentive pools and bonuses	616.469	616,469	0	0	0	0	0	0	0	0

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1		FAILI ZA CLAIM	0 217 (512111 2115				1		
	1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
Reported in Process of Adjustment:										
1.1 Direct	13,694,610	13,694,610								
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	2,786,722	2,786,722								
1.4 Net	10,907,888	10,907,888	0	0	0	0	0	0	0	0
Incurred but Unreported:										
2.1 Direct	9,399,280	9,399,280								
2.2 Reinsurance assumed	0									
2.3 Reinsurance ceded	1,464,536	1,464,536								
2.4 Net	7,934,744	7,934,744	0	0	0	0	0	0	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0									
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded	0									
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct	23,093,890	23,093,890	0	0	0	0	0	0	0	0
4.2 Reinsurance assumed	20,000,000	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	4,251,258	4,251,258	0	0	0	0	0	0	0	0
4.4 Net	18,842,632	18,842,632	0	0	0	n	n	n	n	n
7.7 NOL	10,072,002	10,072,002	U	0						

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

1740.25 740.21010 01	Claims Paid D		and Claim Liability of Current Year	5	6	
	1	2	3	4		Estimated Claim Reserve and Claim
	On Claims Incurred Prior to January 1	On Claims Incurred	On Claims Unpaid December 31 of	On Claims Incurred	Claims Incurred In Prior Years	Liability December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical)	19,027,766	125,241,976	1,090,486	17,752,146	20,118,252	23,096,128
2. Medicare Supplement					0	0
3. Dental Only					0	0
4. Vision Only					0	0
5. Federal Employees Health Benefits Plan					0	0
6. Title XVIII - Medicare					0	0
7 Title XIX - Medicaid					0	0
8. Other health					0	0
9. Health subtotal (Lines 1 to 8)	19,027,766	125,241,976	1,090,486	17,752,146	20,118,252	23,096,128
10. Healthcare receivables (a)		3,258,352			0	0
11. Other non-health					0	0
12. Medical incentive pools and bonus amounts	141, 192			616,469	141, 192	141, 192
13. Totals (Lines 9 - 10 + 11 + 12)	19,168,958	121,983,624	1,090,486	18,368,615	20,259,444	23,237,320

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2016	2017	2018	2019	2020	
1.	Prior	52,797	49,231	49,144	48,869	48,839	
2.	2016	329,503	375,988	376,287	376,107	376,080	
3.	2017	XXX	206,013	231,380	231,736	231,784	
4.	2018	XXX	XXX	241,410	273,626	273,870	
5.	2019	XXX	XXX	XXX	148, 191	167, 124	
6.	2020	XXX	XXX	XXX	XXX	121,984	

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative N	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year					
Year in Which Losses Were Incurred	1 2016	2 2017	3 2018	4 2019	5 2020		
1. Prior		49,231	49,144	48,869	48,839		
2. 2016	380,478	375,988	376,287	376, 107	376,080		
3. 2017	XXX	235,240	232,049	231,736	231,784		
4. 2018	xxx	XXX	286,240	274,099	273,870		
5. 2019	XXX	XXX	XXX	170,954	168,214		
6. 2020	XXX	XXX	XXX	XXX	140,352		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2016	382,653	376,080	9,895	2.6	385,975	100.9				100.9
2. 2017	267,966	231,784	5,245	2.3	237,029	88.5			237,029	88.5
3. 2018	379,263	273,870	8,176	3.0	282,046	74.4			282,046	74.4
4. 2019	242,246	167, 124	17,270	10.3	184,394	76.1	1,090	76	185,560	76.6
5. 2020	184,865	121,984	12,625	10.3	134,609	72.8	18,369	1,541	154,519	83.6

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2016	2017	2018	2019	2020	
1.	Prior	52,797	49,231	49,144	48,869	48,839	
2.	2016	329,503	375,988	376,287	376, 107	376,080	
3.	2017	XXX	206,013	231,380	231,736	231,784	
4.	2018	XXX	XXX	241,410	273,626	273,870	
5.	2019	XXX	XXX	XXX	148, 191	167, 124	
6.	2020	XXX	XXX	XXX	XXX	121,984	

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2016	2017	2018	2019	2020	
1. Prior		49,231	49,144	48,869	48,839	
2. 2016	380,478	375,988	376,287	376, 107	376,080	
3. 2017	XXX	235,240	232,049	231,736	231,784	
4. 2018.	XXX	XXX	286,240	274,099	273,870	
5. 2019	XXX	XXX	XXX	170,954	168,214	
6. 2020	XXX	XXX	XXX	XXX	140,352	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2016		376,080	9,895	2.6		100.9	0	0	385,975	100.9
2.	2017	267,966	231,784	5,245	2.3	237,029	88.5	0	0	237,029	88.5
3.	2018	379,263	273,870	8,176	3.0	282,046	74.4	0	0	282,046	74.4
4.	2019	242,246	167, 124	17,270	10.3	184,394	76.1	1,090	76	185,560	76.6
5.	2020	184,865	121,984	12,625	10.3	134,609	72.8	18,369	1,541	154,519	83.6

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	PART 2D - AC	GGREGATE RESER\	/E FOR ACCIDEN	TAND HEALTH CO	NTRACTS ONLY				
	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
Unearned premium reserves	0				, i				
Additional policy reserves (a)	18,077,240	18,077,240							
Reserve for future contingent benefits									
Reserve for rate credits or experience rating refunds (including									
\$) for investment income	9.413.629	9.413.629							
Aggregate write-ins for other policy reserves		19,739,184	0	0	0	0	0	0	(
6. Totals (gross)	, ,	47,230,053	0			0	0	0	(
7. Reinsurance ceded	0	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							•
8. Totals (Net)(Page 3, Line 4)		47.230.053	0	0	0	0	0	0	(
Present value of amounts not yet due on claims									
10. Reserve for future contingent benefits	0								
11. Aggregate write-ins for other claim reserves		0	0	0	0	0	0	0	(
12. Totals (gross)	0		0	0		0	0	0	(
13. Reinsurance ceded									
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	(
DETAILS OF WRITE-INS									
0501. Risk Adjustment Payable	19,739,184	19,739,184							
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	(
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	19,739,184	19,739,184	0	0	0	0	0	0	(
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	(
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	(

(a) Includes \$18,077,240 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			YSIS OF EXPENSE			
		Claim Adjustme 1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	3 General Administrative Expenses	4 Investment Expenses	5 Total
1.	Rent (\$ for occupancy of	,	F	,	<u> </u>	
	own building)			225.023		225,023
2.	Salary, wages and other benefits					15,602,364
3.	Commissions (less \$, 102, 101				10,002,001
0.	ceded plus \$ assumed)			3, 166, 196		3 166 196
4.	Legal fees and expenses					
5 .	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services			3,033,704		,
	Traveling expenses			32,801		
7.	Marketing and advertising					
8.						537,560
9.	Postage, express and telephone			,		,
10.	Printing and office supplies			ŕ		394,509
11.	Occupancy, depreciation and amortization					152,574
12.	Equipment			49,476		49,476
13.	Cost or depreciation of EDP equipment and software			372,596		372,596
14.	Outsourced services including EDP, claims, and other services	4,131,113	2,926,222	3,980,260	259,212	11,296,807
15.	Boards, bureaus and association fees			146,646		146,646
16.	Insurance, except on real estate			383,451		383,451
17.	Collection and bank service charges					300,030
18.	Group service and administration fees					230,390
19.	Reimbursements by uninsured plans					,
20.	Reimbursements from fiscal intermediaries					
21.	Real estate expenses					
22.	·			,		
23.	Taxes, licenses and fees:					
23.	23.1 State and local insurance taxes			2,281		2 201
				, , ,		,,
	23.2 State premium taxes					200
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes			859,043		859,043
	estate taxes)			427 , 134		427 , 134
24.	Investment expenses not included elsewhere					0
25.	Aggregate write-ins for expenses	0	0	32,769	0	32,769
26.	Total expenses incurred (Lines 1 to 25)	9,736,315	4,468,438	40,765,985	259,212	(a)55,229,950
27.	Less expenses unpaid December 31, current year .		1,616,572	5,245,371		6,861,943
28.	Add expenses unpaid December 31, prior year		1,752,875	5,548,788		7,301,663
29.	Amounts receivable relating to uninsured plans, prior year					0
30.	Amounts receivable relating to uninsured plans, current year					0
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	9,736,315	4,604,741	41,069,402	259,212	55,669,670
	DETAILS OF WRITE-INS					
2501.	Charitable Contributions			5,000		5,000
2502.	Fines and Penalties Expense			27,769		27,769
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25	0	0	32,769	0	32,769
a) Inclu	above) des management fees of \$	to affiliates and \$		n-affiliates.	U	JZ,/09

(a) Includes management fees of \$ to affiliates and \$ to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	
	U.S. government bonds	(-)	
	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)	, ,	
1.3	Bonds of affiliates	(a)	
	Preferred stocks (unaffiliated)		
2.11	Preferred stocks of affiliates	(b)	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		
3.	Mortgage loans	(c)	
4.	Real estate	(d)	
5	Contract Loans		
6	Cash, cash equivalents and short-term investments	(e)534,124	543,008
7	Derivative instruments	(f)	
8.	Other invested assets		
9.	Aggregate write-ins for investment income	0	0
10.	Total gross investment income	1,706,164	1,827,411
11.	Investment expenses		(g)259,212
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		(i)
	Aggregate write-ins for deductions from investment income		* *
16.	Total deductions (Lines 11 through 15)		282.842
	Net investment income (Line 10 minus Line 16)		1,544,569
	DETAILS OF WRITE-INS		, ,
0901.	5217425 51 WW. 2 115		
0902.			
0903.			
	Summary of remaining write-ins for Line 9 from overflow page		0
	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0
1501.	Totals (Ellies 650 Fillia 6500 plus 6550) (Ellie 5, above)		_
1501.			
1502.			
	Summary of remaining write-ins for Line 15 from overflow page		
			0
	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		

EXHIBIT OF CAPITAL GAINS (LOSSES)

investment expenses and \$investment taxes, licenses and fees, excluding federal income taxes, attributable to

(d) Includes \$ for company's occupancy of its own buildings; and excludes \$ interest on encumbrances.

(f) Includes \$ accrual of discount less \$ amortization of premium.

(h) Includes \$ interest on surplus notes and \$ interest on capital notes.

(i) Includes \$ depreciation on real estate and \$ depreciation on other invested assets.

segregated and Separate Accounts.

		1	2	3	4	5
		'	_	o o	7	
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	0	0	0	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	26,083	0	26,083	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans			0	0	0
4.	Real estate		0	0		0
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments			0		
7.	Derivative instruments			0		
8.	Other invested assets	3,820	0	3,820	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	29,903	0	29,903	0	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	DASSEIS		2
		Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		Trondamiled 7 65665	0
	Stocks (Schedule D):			
	2.1 Preferred stocks			0
	2.2 Common stocks			0
3.	Mortgage loans on real estate (Schedule B):			
٥.	3.1 First liens			0
	3.2 Other than first liens.			_
,				
4.	Real estate (Schedule A): 4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income.			_
	4.3 Properties held for sale			_
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			_
6.	Contract loans			0
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			_
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
15.	15.1 Uncollected premiums and agents' balances in the course of collection	1 /1/ 100	71 /100	(1 3/12 711)
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due . 15.3 Accrued retrospective premiums and contracts subject to redetermination			
16			201,241	201,241
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
	Amounts receivable relating to uninsured plans			0
	Current federal and foreign income tax recoverable and interest thereon			0
	Net deferred tax asset			_
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets	449,428	602,002	152,574
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable	260,668	262 , 143	1,475
25.	Aggregate write-ins for other than invested assets	1,352,662	1,473,944	121,282
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)		3,233,572	(551,384)
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0
28.	Total (Lines 26 and 27)	3,784,956	3,233,572	(551,384)
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Miscellaneous Receivables		14,068	(6,502)
2502.	Prepaid Expense		1,444,292	125,003
2503.	Security Deposits		15,584	2,781
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	1,352,662	1,473,944	121,282

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

		Total Members at End of						
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months		
Source of Enfollment	Filor real	i iist Quarter	Second Quarter	Tillia Quarter	Current rear	Member Months		
Health Maintenance Organizations	12 , 189	8,049	7,693	7,374	6,586	91,687		
Provider Service Organizations								
Preferred Provider Organizations	24,873	20,830	20,587	20,123	19,544	245,718		
4. Point of Service								
5. Indemnity Only								
Aggregate write-ins for other lines of business.	0	0	0	0	0	0		
7. Total	37,062	28,879	28,280	27,497	26,130	337,405		
DETAILS OF WRITE-INS								
0601.								
0602.								
0603.								
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0		
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0		

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Maine Community Health Options (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Maine Bureau of Insurance (the "Bureau").

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the Bureau is shown below:

		SSAP#	F/S Page	F/S Line #	2020	2019
		307	. 486	2		2020
<u>NET</u> <u>INCOME</u>						
(1)	Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$56,502,466	\$25,186,844
(2)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP				_	_
(3)	State Permitted Practices that are an increase/(decrease) from NAIC SAP					_
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$56,502,466	\$25,186,844
SURPLUS						
(5)	Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$140,140,003	\$84,188,921
(6)	State Prescribed Practices that are increase/(decrease) from NAIC SAP				_	_
(7)	State Permitted Practices that are an increase/(decrease) from NAIC SAP				_	_
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$140,140,003	\$84,188,921

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC Annual Statement Instructions and NAIC SAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policy

Health premiums are earned over the term of the related insurance policies and reinsurance contracts. Premiums written are reported net of reinsurance ceded and experience rating refunds. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates are subject to approval by the Bureau. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year at the date of acquisition and are reported at amortized cost, which approximates fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the scientific interest method, using yield to maturity.
- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans on real estate.
- (6) Loan-backed securities are stated at either amortized cost or the lower of amortized cost or fair value. The retrospective adjustment method is used to value all securities.
- (7) The Company owns 100% of Community Options LLC.
- (8) The Company has an investment in an unaffiliated limited liability company. The Company reports this investment as an other long-term invested asset on Schedule BA. The asset, which is carried at its Generally Accepted Accounting Principles equity, is nonadmitted for statutory reporting purposes.

- (9) The Company has no derivative instruments.
- (10)The Company uses anticipated investment income as a factor in the premium deficiency reserve calculation.
- (11)Unpaid claims and claims adjustment expenses included management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considered health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claims adjustment expenses are based on assumptions and estimates. While management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continuously reviewed and changes in estimates are incorporated into current period estimates.
- (12) The Company has not modified its capitalization policy from the prior period.
- (13)Pharmaceutical rebate receivables are recorded when earned based on actual rebate receivables billed and an estimate of receivables based on current utilization of specific pharmaceuticals and provider contract terms.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

A. Accounting Changes

There were no accounting changes during the years ended December 31, 2020 and 2019.

B. Corrections of Errors

There were no accounting changes during the years ended December 31, 2020 and 2019.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2020 and 2019.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2020 or 2019.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2020 or 2019.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2020 or 2019.

D. Loan-Backed Securities

- (1) Prepayment assumptions for mortgage-backed securities were obtained from broker-dealer survey values. The Company used various third-party pricing party sources in determining the market value of its loan-backed securities.
- (2) The Company did not recognize other-than-temporary impairments on its loan-backed securities during the years ended December 31, 2020 and 2019.
- (3) The Company did not recognize other-than-temporary impairments on its loan-backed securities during the years ended December 31, 2020 and 2019.
- (4) The Company did not recognize other-than-temporary impairments on its loan-backed securities at December 31, 2020 and 2019.
- (5) The Company had no impaired loan-backed securities for which an other-than-temporary impairment had not been recognized in earnings at December 31, 2020 and 2019.
- (6) The Company had no impaired loan-backed securities at December 31, 2020 and 2019.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

The Company entered into a repurchase investment sweep arrangement whereby the banking institution automatically sweeps excess available account funds into overnight repurchase agreements based on predefined increments. On the next banking day, the funds are returned to the Company's bank accounts. These funds are secured by an obligation of the United States of America. The Company did not enter securities lending transactions during 2020 or 2019.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as a secured borrowing at December 31, 2020 or 2019.

G. Reverse Repurchase Agreements Transaction Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2020 or 2019.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreements transactions accounted for as a sale at December 31, 2020 or 2019.

I. Reverse Repurchase Agreements Transactions Accounted for a Sale

The Company did not enter into reverse repurchase agreements transactions accounted for as a sale at December 31, 2020 or 2019.

J. Real Estate

The Company did not have investments in real estate at December 31, 2020 and 2019.

K. Low-Income Housing Tax Credits (LIHTC)

The Company did not invest in properties generating low-income housing tax credits during 2020 or 2019.

L. Restricted Assets

(1) Restricted Assets (Including Pledged)

	1	2	3	4	5	6	7
	_	2	3	-	3	· ·	,
	Total Gross				Total	Gross	
	(Admitted &	Total Gross		Total	Current	(Admitted &	
	Nonadmitted)			Current		Nonadmitted)	Admitted
	Restricted	Nonadmitted)	Increase/	Year	Admitted	Restricted to	Restricted to
Restricted Asset Category	from Current	Restricted from	(Decrease)	Admitted	Restricted	Total Assets	Total Admitted
,	Year	Prior Year	, ,		(1 minus 4)	(a)	Assets (b)
a. Subject to contractual			,		,	` '	
obligation for which							
liability is not shown	s	\$	\$	Ś	\$		
b. Collateral held under	,	***************************************	,	*	*		
security lending							
agreements							
c. Subject to repurchase							
•							
agreements							•••••
d. Subject to reverse							
repurchase agreements							
e. Subject to dollar							
repurchase agreements							
f. Subject to dollar reverse							
repurchase agreements							
g. Placed under option							
contracts							
h. Letter stock or securities							
restricted as to sale -							
excluding FHLB capital							
stock							
i. FHLB capital stock							
j. On deposit with states		110,579	(459)		110.120	0.049	0.050
k. On deposit with other			(,		===,===		
regulatory bodies							
= :							
I. Pledged collateral to FHLB (including assets backing							
, ,							
funding agreements)							•••••
m. Pledged as collateral not							
captured in other							
categories							•••••
n. Other restricted assets							
o. Total Restricted Assets	\$110,120	\$110,579	\$ (459)	\$	\$ 110,120	0.001	0.001

- (a) Column 1 divided by Asset Page, Column 1, Line 28
- (b) Column 5 divided by Asset Page, Column 3, Line 28
- (2) Detail of Assets Pledged as Collateral Not Captured in Other Categories Not applicable.
- (3) Detail of Other Restricted Assets Not applicable.
- (4) Collateral Received and Reflected as Assets within the Reporting Entity's Financial Statements Not applicable.

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2020 and 2019.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting and netting of assets and liabilities at December 31, 2020 and 2019.

O. 5GI Securities

The Company did not have any 5GI securities at December 31, 2020 and 2019.

P. Short Sales

The Company did not have any short sales at December 31, 2020 and 2019.

Q. Prepayment Penalty and Acceleration Fees

The Company did not have any prepayment penalty or acceleration fees at December 31, 2020 and 2019.

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company had no investments in joint ventures, partnerships or limited liability companies that exceeded 10% of its admitted assets at December 31, 2020 or 2019.
- B. Not applicable.

7. Investment Income

- A. All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- B. At December 31, 2020 and 2019 there was no non-admitted accrued investment income.

8. Derivative Instruments

The Company had no derivative instruments at December 31, 2020 or 2019.

9. Income Taxes

The Company is exempt from Federal income taxes under Section 501(c)(29) of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements. The Company's federal income tax return is not consolidated with any other entity.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. Nature of the Relationship: The Company owns 100% of Community Options, LLC.
- B. Significant Transactions for Each Period: Not applicable.
- C. Transactions with Related Parties not Reported on Schedule Y: Not applicable.
- D. Amounts Due from or to Related Parties: Not applicable.
- E. Management and Service Contracts and Cost Sharing Arrangements: Not applicable.
- F. Guarantees or Undertakings: Not applicable.
- G. Nature of Control Relationships that Could Affect Operations or Financial Position: Not applicable.
- H. Amount Deducted for Investment to Upstream Company: Not applicable.
- I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets: Not applicable.
- J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated Companies ("SCA"): Not applicable.
- K. Investment in a Foreign Insurance Subsidiary: Not applicable.

- L. Investments in Downstream Non-Insurance Holding Companies: Not applicable.
- M. All SCA investments: Not applicable.
- N. Investment in Insurance SCAs: Not applicable.
- O. SCA and SSAP No. 48 Entity Loss Tracking: Not applicable.

11. Debt

A. Debt, including Capital Notes

At December 31, 2020 and 2019 the Company had outstanding a note payable, with a face value and a carry value of \$185,239 and \$257,043 to Mill 2 Storehouse, LLC, for expenses related to leasehold improvements. The note payable was issued May 1, 2014 (the commencement date) and is payable in monthly principal and interest payments of \$7,106 until April 2023. The note is contingent upon the Company remaining in the leased space. If the Company does not renew the lease after the initial five year term, the note will become due 60 days after cancellation. The note carries interest at 6%. During 2020 and 2019, the Company paid interest of \$13,469 and \$17,641 on this note. This note is off-set against leasehold improvements in line 21 of the Asset Schedule.

At December 31, 2020 and 2019 the Company had outstanding a note payable, with a face value and a carry value of \$139,463 and \$193,522 to Mill 2 Storehouse, LLC, for expenses related to leasehold improvements. The note payable was issued October 1, 2014 (the commencement date) and is payable in monthly principal and interest payments of \$5,350 until April 2023. The note is contingent upon the Company remaining in the leased space. If the Company does not renew the lease after the initial five (5) year term, the note will become due 60 days after cancellation. The note carries interest at 6%. During 2020 and 2019, the Company paid interest of \$10,141 and \$13,281 on this note.

.

Debt maturities subsequent to December 31, 2020 consist of:

2021	\$	133,627
2022		141,868
2023		49,207
2024		-
2025 or after	_	
Total	\$	324,702

The Company does not have any reverse repurchase agreements at December 31, 2020 or 2019.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB Agreements outstanding at December 31, 2020 or 2019.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable.

- B. Not Applicable
- C. Not applicable
- D. Not applicable.

E. Defined Contribution Plan

The Company maintains a Section 401(k) Retirement Plan for its employees. For the years ended December 31, 2020 and 2019, elective employee deferrals were matched by the Company in an amount equal to 100% of such deferrals up to a maximum match of 3% of compensation plus 50% of such elective deferrals equal to more than 3% but not exceeding 5% of compensation. The Company's contribution to the plan was \$345,680 and \$438,520 for 2020 and 2019, respectively.

The Company owns a Section 457(b) Plan (the "Plan") for its employees. The Plan limits participation to a select group of management or highly compensated employees (or "top hat" group) and is exempt from most Employee Retirement Income Security Act of 1974 requirements. During 2020, the Company executed fund withdrawals of \$22,320, with an initial cost of \$18,500 resulting in a realized gain of \$3,820. The value of the Plan funds was \$144,000 and \$162,500 at December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019 the fair market value of the funds is \$214,127 and \$215,318, respectively.

F. Multiemployer Plans

Not applicable.

G. Consolidated/Holding Company Plans

Not applicable.

H. Postemployment Benefits and Compensated Absences

Liabilities for earned not yet taken vacation benefits have been accrued as of December 31, 2020 and 2019.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. **Outstanding Shares:** The Company has no outstanding shares.
- B. Preferred Stock: The Company has no preferred stock outstanding.
- C. **Dividend Restrictions:** Not applicable.
- D. **Dividends Paid:** Not applicable.
- E. Maximum Ordinary Dividend during 2020: Not applicable.
- F. **Unassigned Surplus Restrictions:** There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- G. Mutual Surplus Advances: Not applicable.
- H. Company Stock Held for Special Purpose: Not applicable.

- I. Changes in Special Surplus Funds: The change in the balance of special surplus funds from the prior year is due to changes in the amounts segregated for the Affordable Care Act ("ACA") health insurer fee. The insurer fee was suspended for fee years beginning after December 31, 2020; therefore no surplus was segregated as of December 31, 2020.
- J. Changes in Unassigned Funds: Not applicable.
- K. Surplus Notes: The Company issued the following surplus debentures or similar obligations

1	2	3	4	5	6	7	8
				Is Surplus		Carrying	Unapproved
				Note Holder	Carrying Value	Value of	Interest
Item		Interest	Original Issue	a Related	of	Note Current	And/Or
Number	Date Issued	Rate	Amount of Note	Party (Y/N)	Note Prior Year	Year *	Principal
1001	03/29/2012	0.000%	\$ 12,506,124	N	\$ 12,506,124	\$ 12,506,124	\$ -
1002	02/22/2013	0.370%	\$119,810,000	N	\$119,810,000	\$119,810,000	\$ 2,501,643
Total	XXX	XXXX	\$132,316,124	XXX	\$132,316,124	\$132,316,124	\$ 2,501,643

^{*} Total should agree with Page 3, Line 29.

1	9	10	11	12	13	14
			Current Year			
			Interest Offset			
			Percentage (not			
	Current Year	Life-To-Date	including amounts			
Item	Interest Expense	Interest Expense	paid to a 3rd party	Current Year	Life-To-Date	
Number	Recognized	Recognized	liquidity provider).	Principal Paid	Principal Paid	Date of Maturity
1001	\$ -	\$ -	=	\$ -	\$ -	08/12/2020
1002	\$ -	\$ -	=	\$ -	\$ -	12/30/2030
Total	\$ -	\$ -	XXX	\$ -	\$ -	XXX

1	1 15 16 17		18	19	
ltem Number	Are Surplus Note payments contractually linked? (Y/N)	Surplus Note payments subject to administrative offsetting provisions?	Were Surplus Note proceeds used to purchase an asset directly from the holder of the surplus note? (Y/N)	Is Asset Issuer a Related Party (Y/N)	Type of Assets Received Upon Issuance
1001	Υ	N	N	N	Cash
1002	Υ	N	N	N	Cash
Total	XXX	XXX	XXX	XXX	XXX

1	20	21	22
			Is Liquidity Source
	Principal Amount of		a Related Party to
Item	Assets Received	Book/Adjusted Carry	the Surplus Note
Number	Upon Issuance	Value of Assets	Issuer? (Y/N)
1001	\$ 12,506,124	\$ 12,506,124	N
1002	\$119,810,000	\$119,810,000	N
Total	\$132,316,124	\$132,316,124	XXX

At December 31, 2020 and 2019, the surplus notes had carrying values of \$119,810,000 and \$12,506,124. Under the terms of the \$119,800,000 surplus notes, each individual draw is repayable fifteen years from the date of the draw, with the last repayment due December 30, 2030. Under the terms of the \$12,506,124 surplus notes, each individual draw is repayable five years from the date of the draw, with the last repayment due August 12, 2020. Accrued interest payments are due annually beginning in 2020 for draws made prior to 2019. Interest rates for the surplus notes of \$119,810,000 and \$12,506,124 are accrued at 0.37% and 0.00%, respectively.

The surplus note has the following repayment conditions and restrictions: Each payment of interest on and principal of the surplus note may be made only with the prior approval of the Commissioner of Insurance of the State of Maine and only to the extent the Company has sufficient surplus earnings to make such payment. During 2020 and 2019, the Company made no interest or principal payments and, because interest payments have not

been approved by the Commissioner of Insurance, accrued interest on the surplus note is excluded from these financial statements.

The surplus note has the following subordination terms: Because the intent of the note is to provide financing that meets the definition of "risk based capital" for State Insurance Laws purposes, the note will have a claim on cash flow and reserves of the Company that is subordinate to (a) claims payments, (b) basic operating expenses, and (c) maintenance of required reserve funds while the Company is operating as a CO-OP under State Insurance Laws.

- L. Restatement Due to Prior Quasi-Reorganizations: The Company had no restatements due to prior quasi-reorganizations.
- M. **Quasi-Reorganizations over Prior 10 Years:** The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company has no contingent commitments at December 31, 2020 and 2019.

B. Assessments

The Company has identified no assessments that could have a material financial effect on these statements at December 31, 2020 and 2019.

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2020 and 2019.

D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

At December 31, 2020 and 2019, the Company reported admitted assets of \$1,242,040 and \$596,963, respectively, in premiums receivable due from policyholders. Based upon Company experience, any uncollectible receivables are not expected to exceed \$617,663 that was nonadmitted at December 31, 2020; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Leases

(1) The Company leases office space under various non-cancelable operating leases. Related lease expense for 2020 and 2019 was \$225,023 and \$233,379, respectively.

Certain rental commitments have renewal options extending until April 2023 and include incremental increases in the per-foot cost each year. Certain rental commitments include favorable purchase options at the end of the lease term.

(2) At December 31, 2020, the minimum aggregate rental commitments are as follows:

Year Ended	Operating
December 31,	Leases
2021	\$ 216,667
2022	226,667
2023	76,666
Total	\$ 520,000

(3) The Company is not involved in any sales-leaseback transactions.

B. Lessor Leases

- (1) The Company has not entered into any operating leases.
- (2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company had no financial instruments with off-balance sheet risk at December 31, 2020 and 2019.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2020, there were no significant concentrations

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2020 and 2019.

B. Transfer and Servicing of Financial Assets

Not applicable at December 31, 2020 or 2019.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance yield on the investments.
- (2) At December 31, 2020 and 2019, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

- A. Administrative Services Only Plans: Not applicable.
- B. Administrative Services Contract Plans: Not applicable.
- C. Medicare or Similarly Structured Cost-Based Reimbursement Contract: Not applicable.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company had no premiums written by managing general agents or third party administrators during the years ended December 31, 2020 and 2019.

20. Fair Value Measurements

A. Fair Value Measurements

The Company had no material assets or liabilities measured and reported at fair value at December 31, 2020.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable.

C. Financial Instruments

Certain of the Company's financial instruments are measured at fair value. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP. The following are the levels of the hierarchy and a brief description of the type of valuation information (inputs) that qualifies a financial asset or liability for each level:

- Level 1 Unadjusted quoted prices for identical assets or liabilities in active markets.
- Level 2 Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
- Level 3 Developed from unobservable data, reflecting the Organization's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classify these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

There have been no significant changes in the valuation techniques during 2020.

The carrying values and estimated fair values of the Company's financial instruments at December 31, 2020 were as follows:

Type of Financial	Aggregate Fair	Admitted				Net Asset Value	Not Practicable
Instrument	Value	Assets	(Level 1)	(Level 2)	(Level 3)	(NAV)	(Carrying Value)
Bonds	\$70,925,403	\$68,950,865	\$	\$70,925,403	\$	\$	\$
Cash Equivalents	\$77,646,032	\$77,646,032	\$77,646,032	\$	\$	\$	\$

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value at December 31, 2020 and 2019.

E. Investments Measured at Net Asset Value

The Company has investments measured at net asset value at December 31, 2020 and 2019.

21. Other Items

- A. Unusual or Infrequent Items: Not applicable.
- B. Troubled Debt Restructuring: Debtors: Not applicable.
- C. Other Disclosures:

Bonds with an amortized cost of \$110,120 and \$110,579 were on deposit with a regulatory authority at December 31, 2020 and 2019.

- **D.** Business Interruption Insurance Recoveries: Not applicable.
- E. State Transferable and Non-transferable Tax Credits: Not applicable.
- F. Subprime-Mortgage-Related Risk Exposure: Not applicable.
- G. Retained Assets: Not Applicable.
- H. Insurance-Linked Securities (ILS) Contracts: Not applicable.
- I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy: Not Applicable

22. Events Subsequent

The Company was subject to an annual fee under Section 9010 of the Federal ACA. This annual fee was allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee became payable once the entity provided health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee was due. The annual fee under Section 9010 of the ACA was permanently repealed beginning January 1, 2021.

A. Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act (YES/NO)? Yes

			<u>C</u>	<u>urrent Year</u>	Prior Year
В.	ACA fee assessment payable for the upcoming year		\$	-	\$ 2,256,974
C.	ACA fee assessment paid		\$	2,120,462	\$ -
D.	Premium written subject to ACA 9010 assessment		\$ 2	200,040,163	\$ 262,554,620
Ε.	Total Adjusted Capital before surplus adjustment		\$ 1	140,140,003	
F.	Total Adjusted Capital after surplus adjustment		\$ 1	140,140,003	
G.	Authorized Control Level		\$	7,238,898	
Н.	Would reporting the ACA assessment as of December				
	31, 2020, have triggered an RBC action level (YES/NO)?	No			

Subsequent events have been considered through February 26, 2021 for the statutory statements issued on February 28, 2021. There were no other events occurring subsequent to December 31, 2020 requiring disclosure.

23. Reinsurance

A. Ceded Reinsurance Report.

Section 1 – General Interrogatories

1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly by the Company or by any representative, officer, trustee or director of the Company?

Yes () No (X)

2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, beneficiary, a creditor or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 - Ceded Reinsurance Report - Part A

1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

Yes () No (X)

2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsurance policies?

Yes () No (X)

Section 3 - Ceded Reinsurance Report - Part B

- 1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate. Not applicable
- 2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance as of December 31, 2020 and 2019.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during the years ended December 31, 2020 and 2019.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not applicable at December 31, 2020 and 2019.

E. Reinsurance Credit

Not applicable at December 31, 2020 and 2019.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.

- **B.** The Company records retrospective premium as an adjustment to earned premium.
- **C.** The amount of premiums written by the Company at December 31, 2020 that was subject to retrospective rating features was \$199,380,490, which represented 100% of the total net premiums written.
- **D.** Medical loss ratio rebates required pursuant to the Public Health Service Act.

	1 Individual	2 Small Group Employer	3 Large Group Employer	4 Other Categories with Rebates	5 Total
Prior Reporting Year					
(1) Medical loss ratio rebates incurred	\$ 2,776,224	-	\$ 567,805	-	\$ 3,344,029
(2) Medical loss ratio rebates paid	_	-	-	-	-
(3) Medical loss ratio rebates unpaid	\$ 2,776,224	-	\$ 567,805	-	\$ 3,344,029
(4) Plus reinsurance assumed amounts	XXXX	XXXX	xxxx	XXXX	xxxx
(5) Less reinsurance ceded amounts	XXXX	XXXX	xxxx	XXXX	XXXX
(6) Rebates unpaid net of reinsurance	XXXX	XXXX	xxxx	XXXX	xxxx
Current Reporting Year-to- Date					
(1) Medical loss ratio rebates incurred	\$ 15,055,166	-	\$ 547,364	-	\$ 15,602,531
(2) Medical loss ratio rebates paid	\$ 8,874,204	-	\$ 658,726	-	\$ 9,532,930
(3) Medical loss ratio rebates unpaid	\$ 8,957,186	-	\$ 456,443	-	\$ 9,413,629
(4) Plus reinsurance assumed amounts	XXXX	XXXX	xxxx	XXXX	xxxx
(5) Less reinsurance ceded amounts	XXXX	XXXX	XXXX	XXXX	xxxx
(6) Rebates unpaid net of reinsurance	xxxx	xxxx	xxxx	XXXX	xxxx

E. Risk Sharing Provisions of the Affordable Care Act

(1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)?

Yes

(2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year

for the Current Year	AMOUNT
a. Permanent ACA Risk Adjustment Program	
Assets	
1. Premium adjustments receivable due to ACA Risk Adjustment (including high-risk	payments) \$ 0
Liabilities	
2. Risk adjustment user fees payable for ACA Risk Adjustment	46,499
3. Premium adjustments payable due to ACA Risk Adjustment (including high-risk pa	yments) 7,791,670
Operations (Revenue & Expense)	
4. Reported as revenue in premium for accident and health contracts (written/collect ACA Risk Adjustment	cted) due to (7,791,670)
5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	34,371
b. Transitional ACA Reinsurance Program	
Assets	
1. Amounts recoverable for claims paid due to ACA Reinsurance	0
2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)	0
3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsura	ance 0
Liabilities	
4. Liabilities for contributions payable due to ACA Reinsurance – not reported as ced	led premium 0
5. Ceded reinsurance premiums payable due to ACA Reinsurance	0
6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsura	nce 0
Operations (Revenue & Expense)	
7. Ceded reinsurance premiums due to ACA Reinsurance	0
8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or	expected
payments	0
9. ACA Reinsurance contributions – not reported as ceded premium	0
c. Temporary ACA Risk Corridors Program	
Assets	
1. Accrued retrospective premium due to ACA Risk Corridors	0
Liabilities	
2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corrid	lors 0
Operations (Revenue & Expense)	
3. Effect of ACA Risk Corridors on net premium income (paid/received)	0
4. Effect of ACA Risk Corridors on change in reserves for rate credits	0

NOTES TO FINANCIAL STATEMENTS

(3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any non-admission) and liability balances along with the reasons for adjustments to prior year balance.

reasons for adjustments to prior year balance.											
	Accrued I	During the	Received or	Paid as of							
	Prior Year on Business		the Current Year on						Unsettled Balances as of		
	Written		Business		Differences		Adjustments			the Reporting Date	
	Before De	c 31 of the	Written Bef	ore Dec 31		Prior Year				Cumulative	Cumulative
	Prior	r Year	of the Pr	ior Year	Prior Year	Accrued				Balance	Balance
					Accrued Less	Less	To Prior	To Prior		from Prior	from Prior
					Payments	Payments	Year	Year		Years (Col 1	
					(Col 1 - 3)	(Col 2 - 4)	Balances	Balances		- 3 + 7)	2-4+8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivable		Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. Permanent ACA Risk	receivable	(i dydbic)	Receivable	(i dydbic)	Receivable	(i dydbic)	Receivable	(i dyabic)	INCI	receivable	(i dydbic)
Adjustment Program											
, ,											
1. Premium adjustments											
receivable (including high-											
risk payments)	0	0	205,037	0	(205,037)	0	205,307	0	Α	0	0
2. Premium adjustments											
(payable) (including high-											
risk payments)	0	36,400,000	0	.8,191,423	0	.28,208,577	0	(8,469,393)	В	0	.19,739,184
3. Subtotal ACA Permanent								, , , ,			
Risk Adjustment Program	_	36.400.000	205 037	Q 101 //22	(205,037)	28 208 577	205 307	(8 460 303)		0	0
b. Transitional ACA Reinsurance		30,400,000	203,037	.0,131,423	(203,037)	.20,200,377	203,307	(8,405,555)			
Program											
1. Amounts recoverable for											
claims paid	0	0	0	0	0	0	0	0	С	0	0
2. Amounts recoverable for											
claims unpaid (contra											
liability)	0	0	0	0	0	0	0	0	D	0	0
3. Amounts receivable relating											
	0	l0	0	n	0	٥ .	0	n	F	n	0
·									-		
4. Liabilities for contributions											
payable due to ACA											
Reinsurance - not reported		_	_	_	_	_	_		_	_	
as ceded premium	0	0	0	0	0	0	0	0	F	0	0
5. Ceded reinsurance											
premiums payable	0	0	0	0	0	0	0	0	G	0	0
6. Liability for amounts held											
under uninsured plans	0	lo	0	0	0	0	0	0	н	0	0
7. Subtotal ACA Transitional					•						
	0	0	0	0	0	_	0	0		0	0
Reinsurance Program	0		0	0	0			0		0	
c. Temporary ACA Risk Corridors											
Program											
Accrued retrospective											
premium	201,241	0	.58,939,101	0	(58,737,860)	0	58,737,860	0	1	0	0
2. Reserve for rate credits or											
policy experience rating											
refunds	0	0	0	0	0	0	0	0	J	0	0
Subtotal ACA Risk Corridors									-		
	201 241	_	E0 020 101	_	(58,737,860)	_	E0 727 060	_		_	_
Program	201,241	0	.50,959,101	0	(30,/3/,000)		58,737,860	0		0	
d. Total for ACA Risk Sharing	204 244	20 400 000	FO 144 427	0 104 433	(EB 043 006)	20 200 577	F0 042 007	(0.400.303)		_	10 720 401
Provisions	201,241	.36,400,000	.59,144,137	8,191,423	(58,942,896)	.28,208,577	.58,942,897	(8,469,393)		0	.19,739,181

Explanation of Adjustments

- A Adjustment was made to reflect the ending balance as reported in the Centers for Medicare & Medicaid Services "Summary Report on Transitional Reinsurance Payments and Permanent Risk Adjustment Transfers for the 2019 Benefit Year"
- B Adjustment was made to reflect the ending balance as reported in the Centers for Medicare & Medicaid Services "Summary Report on Transitional Reinsurance Payments and Permanent Risk Adjustment Transfers for the 2019 Benefit Year"
- C Not Applicable
- D Not applicable
- E Not applicable
- F Not applicable
- G Not applicable
- H Not applicable
- l Adjustment was made to reflect the settlement of the Risk Corridor Program for 2015 and 2016 program years
- J Not applicable

(4) Roll forward of Risk Corridors Asset and Liability Balances by Program Benefit Year.

Risk Corridors Program Year	Prior Year on Business Written		Received or Paid as of the Current Year on Business Written Before Dec 31 of the Prior Year				Adjustments		Unsettled Balances as of the Reporting Date Cumulative		
					,	Accrued Less Payments	To Prior Year Balances	To Prior Year			Years (Col 2
	1	2	3	4	(Col 1 - 3)	(Col 2 - 4)	7	Balances 8		(Col 1 - 3 + 7)	- 4 + 8) 10
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. 2014 1. Accrued retrospective premium	0	0	0	0	0	0	0	0	В	0	0
c. 2016 1. Accrued retrospective premium		0	0	0	0	0	35,998,655 0 .58,737,860	0	F	0	0

Explanation of Adjustments

- A Not applicable
- B Not applicable
- C Adjustment was made to reflect the settlement of the Risk Corridor Program for 2015 program year
- D Not applicable
- E Adjustment was made to reflect the settlement of the Risk Corridor Program for 2016 program year
- F Not applicable

24(4)d (Columns 1 through 10) should equal 24E(3)c3 (Column 1 through 10 respectively)

(5) ACA Risk Corridors Receivable as of Reporting Date

	1	2	3	4	5	6
	Estimated					
	Amount to be	Non-Accrued		Asset Balance		
	Filed or Final	Amounts for		(Gross of Non-		Net Admitted
Risk Corridors	Amount Filed with	Impairment or	Amounts received	admissions)		Asset
Program Year	CMS	Other Reasons	from CMS	(1-2-3)	Non-admitted	(4-5)
a. 2014	241,717	0	241,717	0	0	0
b. 2015	22,739,205	0	22,739,205	0	0	0
c. 2016	35,998,655	0	35,998,655	0	0	0
e. Total (a+b+c)	58,979,577	0	58,979,577	0	0	0

24E(5)d (Columns 4) should equal 24E(3)c1 (Column 9)

24E(5)d (Columns 6) should equal 24E(2)c1

On April 27, 2020, the US Supreme Court (the Court) ruled in favor of the Company and certain other health insurance companies concerning their entitlement to reimbursement from the US Government for claim payments subject to the Risk Corridors Program during the first three years of the Affordable Care Act (2014-2016). On September 25, 2020, the Company received \$58,939,101 from the United States as payment for the 2014-2016 risk corridor amounts.

25. Change in Incurred Claims and Claim Adjustment Expenses

- A. Reserves as of December 31, 2020 were \$21,075,673. As of December 31, 2020, \$20,921,834 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$1,166,820 as a result of re-estimation of unpaid claims and claim adjustments expenses principally on the comprehensive line of business. Therefore, there has been a \$2,901,540 favorable prior year development since December 31, 2019 to December 31, 2020. The decrease is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.
- **B.** There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid claims and claim adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2020 and 2019.

27. Structured Settlements

Not applicable at December 31, 2020 and 2019.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

	Estimated Pharmacy			Actual	Actual
	Rebates as	Pharmacy		Rebates	Rebates
		Rebates as	Actual Rebates	Received	Received
	Reported on	Billed or	Received	Within 91 to	More Than
	Financial	Otherwise	Within 90 Days	180 Days of	180 Days After
Quarter	Statements	Confirmed	of Billing	Billing	Billing
12/31/2020	\$ 1,979,071	\$ 1,271,773	\$ -	\$ -	\$ -
09/30/2020	\$ 1,030,659	\$ 1,340,135	\$ -	\$ -	\$ -
06/30/2020	\$ 2,510,777	\$ 1,519,333	\$ -	\$ 1,615,029	\$ -
03/31/2020	\$ 2,235,403	\$ 1,536,263	\$ -	\$ 1,521,155	\$ (43,753)
12/31/2019	\$ 2,360,590	\$ 1,878,649	\$ -	\$ 2,354,440	\$ (11,601)
09/30/2019	\$ 2,151,282	\$ 1,642,123	\$ -	\$ 2,175,246	\$ 41,726
06/30/2019	\$ 2,756,688	\$ 1,719,801	\$ -	\$ 2,168,705	\$ 115,054
03/31/2019	\$ 1,445,755	\$ 1,881,458	\$ -	\$ 1,985,523	\$ 76,188
12/31/2018	\$ 2,839,602	\$ 2,235,691	\$ -	\$ 2,884,512	\$ (2,993)
09/30/2018	\$ 2,620,684	\$ 2,389,322	\$ -	\$ 2,404,907	\$ 182,272
06/30/2018	\$ 2,455,135	\$ 2,093,450	\$ -	\$ 2,389,322	\$ 126,068
03/31/2018	\$ 2,517,225	\$ 2,204,950	\$ -	\$ 2,201,335	\$ 155,040

B. Risk Sharing Receivables

Not applicable at December 31, 2020 and 2019.

29. Participating Policies

Not applicable at December 31, 2020 and 2019.

NOTES TO FINANCIAL STATEMENTS

30. Premium Deficiency Reserves

The Company recorded a premium deficiency reserves at December 31, 2020.

Liability carried for premium deficiency reserves
 Date of the most recent evaluation of this liability
 Was anticipated investment income utilized in the calculation?
 Yes X No

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation recoveries in its determination of the liability for unpaid claims and reduced such liability by \$0 for the years ended December 31, 2020 and 2019.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? If yes, complete Schedule Y, Parts 1, 1A and 2				
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superisuch regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registratic providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commits Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the resubject to standards and disclosure requirements substantially similar to those required by such Act and regulation	on statement issioners (NAIC) in eporting entity	.] No [X] N/A []	
1.3	State Regulating?		Mai	ne	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [] No [X]	
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group	<u> </u>			
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or de reporting entity?		Yes [] No [X]	
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made	······	12/31/	2 017	
3.2	State the as of date that the latest financial examination report became available from either the state of domicile of entity. This date should be the date of the examined balance sheet and not the date the report was completed or re-		12/31/	² 2017	
3.3	State as of what date the latest financial examination report became available to other states or the public from eith domicile or the reporting entity. This is the release date or completion date of the examination report and not the date examination (balance sheet date).	ate of the	10/04/	/2019	
3.4	By what department or departments? Maine Bureau of Insurance				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a substatement filed with Departments?] No [] N/A [X]	
3.6	Have all of the recommendations within the latest financial examination report been complied with?	Yes [] No [] N/A [X]	
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service combination thereof under common control (other than salaried employees of the reporting entity), receive credit of a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business? 4.12 renewals?	commissions for or control	Yes [] No [X]	
4.2	During the period covered by this statement, did any sales/service organization owned in whole or in part by the represent credit or commissions for or control a substantial part (more than 20 percent of any major line of business premiums) of:	porting entity or an affiliate, measured on direct		1 [//]	
	4.21 sales of new business?] No [X]] No [X]	
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [] No [X]	
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation ceased to exist as a result of the merger or consolidation.	i) for any entity that has			
	1 Name of Entity NAIC Company Code St	3 ate of Domicile			
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, revoked by any governmental entity during the reporting period?] No [X]	
6.2	If yes, give full information:				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity] No [X]	
7.2	If yes, 7.21 State the percentage of foreign control; 7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the national attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney-in-fact;	lity of its manager or	· <u>·</u>	9	
	1 2 Nationality Type of Entity				

8.2	If response to 8.1 is yes, please identify the name of the bank holding of					Yes [1	INU	[X]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fill fresponse to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	rms? (city and state of the main office) of any affiliate Office of the Comptroller of the Currency (OCC	es regulate	d by a fee	deral	Yes []	No	[X]
	1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC			
9.	What is the name and address of the independent certified public according KPMG LLC One Financial Plaza 755 Main Street Hartford, CT 0	<u> </u>	e annual a	nudit?					
	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reportillaw or regulation?	ing Model Regulation (Model Audit Rule), or sub	stantially s	imilar sta	ate	Yes []	No	[X]
10.2	If the response to 10.1 is yes, provide information related to this exemp	ption:							
10.3 10.4	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin If the response to 10.3 is yes, provide information related to this exemption	uirements of the Annual Financial Reporting Moonilar state law or regulation?ption:	lel Regula	tion as		Yes []	No	[X]
10.5 10.6	Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain	e with the domiciliary state insurance laws?			Yes [X] No []	N/	A []
11.	What is the name, address and affiliation (officer/employee of the repo firm) of the individual providing the statement of actuarial opinion/certif Kathleen Ely FSA, MAAA, Milliman 80 Lamberton Road Windsor, C	orting entity or actuary/consultant associated witl fication?	n an actua	rial consu	llting				
12.1	Does the reporting entity own any securities of a real estate holding co	•				Yes []	No	[X]
		estate holding company							
	·	rcels involved							
12.2	12.13 Total book/adj	usted carrying value				\$			
13. 13.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI What changes have been made during the year in the United States m	nanager or the United States trustees of the repo	orting entity	y?					
13.2	Does this statement contain all business transacted for the reporting el					Yes []	No	[]
13.3	Have there been any changes made to any of the trust indentures during	ng the year?				Yes [
	If answer to (13.3) is yes, has the domiciliary or entry state approved the] No []	N/	A []
14.1	Are the senior officers (principal executive officer, principal financial off similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual or relationships:	ich includes the following standards?	· .			Yes [)	(]	No	[]
	 b. Full, fair, accurate, timely and understandable disclosure in the period c. Compliance with applicable governmental laws, rules and regulation d. The prompt internal reporting of violations to an appropriate person 	ns;	entity;						
14.11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:								
14.2 14.21	Has the code of ethics for senior managers been amended?	nt(s).				Yes []	No	[X]
	Have any provisions of the code of ethics been waived for any of the split the response to 14.3 is yes, provide the nature of any waiver(s).					Yes []	No	[X]

15.1		entity the beneficiary of a Letter of Credit that is unrelated to reinsurance				Yes [. 1	No [X 1
15.2	If the response to	o 15.1 is yes, indicate the American Bankers Association (ABA) Routing er of Credit and describe the circumstances in which the Letter of Credit i	Number a	and the name of the issuing or confirm	ning	100 [,	110 [^ 1
	1 American Bankers Association (ABA) Routing	2		3			4		
	Number			hat Can Trigger the Letter of Credit			Amou		
		BOARD OF DIREC							
16.		or sale of all investments of the reporting entity passed upon either by the	e board of	f directors or a subordinate committee		Yes [: X 1	No [1
17.	Does the reporting	ng entity keep a complete permanent record of the proceedings of its boa	ard of dire	ectors and all subordinate committees	;			No [,
18.	Has the reporting	g entity an established procedure for disclosure to its board of directors of officers, directors, trustees or responsible employees that is in conflict with the conflict wit	or trustees	of any material interest or affiliation of	on the			No []
		FINANCIAL	_						
19.		ent been prepared using a basis of accounting other than Statutory Accouciples)?				Yes [. 1	No [X 1
20.1	Total amount loa	aned during the year (inclusive of Separate Accounts, exclusive of policy	loans):	20.11 To directors or other officers		\$			0
				20.12 To stockholders not officers		.\$			0
				20.13 Trustees, supreme or grand (Fraternal Only)		œ.			٥
20.2	Total amount of	loans outstanding at the end of year (inclusive of Separate Accounts, exc	clusive of	(Fraternal Only)		Φ			0
	policy loans):	tourie outstanding at the one of your (moustle of copulate / locounte, ext	0100110 01	20.21 To directors or other officers		.\$			0
				20.22 To stockholders not officers		\$			0
				20.23 Trustees, supreme or grand (Fraternal Only)		\$			0
21.1		s reported in this statement subject to a contractual obligation to transfer reported in the statement?		r party without the liability for such					
21.2		amount thereof at December 31 of the current year:		21.21 Rented from others					
		·		21.22 Borrowed from others		\$			
				21.23 Leased from others					
				21.24 Other		\$			
22.1	Does this statem guaranty associa	nent include payments for assessments as described in the Annual State ation assessments?	ement Inst	ructions other than guaranty fund or		Yes [. 1	No [Х]
22.2	If answer is yes:			.21 Amount paid as losses or risk adj					
			22	.22 Amount paid as expenses		\$			
				.23 Other amounts paid					
		ng entity report any amounts due from parent, subsidiaries or affiliates or ny amounts receivable from parent included in the Page 2 amount:							
		INVESTMEN	ΙΤ						
24.01		cks, bonds and other securities owned December 31 of current year, ove ssion of the reporting entity on said date? (other than securities lending p				Yes	[X]	No []
24.02	, 0	d complete information relating thereto							
24.03	whether collatera	nding programs, provide a description of the program including value for all is carried on or off-balance sheet. (an alternative is to reference Note 1	17 where	this information is also provided)					
24.04		entity's securities lending program, report amount of collateral for confor				.\$			
24.05	For the reporting	entity's securities lending program, report amount of collateral for other	programs	i		\$			
24.06		rities lending program require 102% (domestic securities) and 105% (forentract?			Yes [] No	[] N/A	[X]
24.07	Does the reporti	ng entity non-admit when the collateral received from the counterparty fa	alls below	100%?	Yes [] No	[] N/A	[X]
24.08		ng entity or the reporting entity's securities lending agent utilize the Mastes lending?			Yes [] No	[] N/A	[X]

24.09	For the reporting entity's securities lending program state the	e amount of the following as of December 31 of the current year:				
	24.091 Total fair value of reinvested collater	al assets reported on Schedule DL, Parts 1 and 2.	\$	0		
	24.092 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2					
25.1	Were any of the stocks, bonds or other assets of the reporting control of the reporting entity, or has the reporting entity sold	eported on the liability page				
25.2	If yes, state the amount thereof at December 31 of the currer	nt year: 25.21 Subject to repurchase agreements	s 63.30/	5 000		
20.2	in yee, state the amount thereof at Bosoniber of a the same	25.22 Subject to reverse repurchase agreements	\$			
		25.23 Subject to dollar repurchase agreements				
		25.24 Subject to reverse dollar repurchase agreements 25.25 Placed under option agreements 25.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	\$ \$			
		25.27 FHLB Capital Stock	.\$ \$ 110	0 120		
		25.29 On deposit with other regulatory bodies	\$			
		25.30 Pledged as collateral - excluding collateral pledged to an FHLB) •			
		25.31 Pledged as collateral to FHLB - including assets backing funding agreements	.\$ \$			
		20.02 Offici	Ψ			
25.3	For category (25.26) provide the following:					
	1 Nature of Restriction	2 Description	3 Amount			
	Nature of Nestriction	Description				
26.1 26.2		orted on Schedule DB? ram been made available to the domiciliary state?Yes [
LINES 2	6.3 through 26.5: FOR LIFE/FRATERNAL REPORTING ENT	TITIES ONLY:				
26.3	Does the reporting entity utilize derivatives to hedge variable	annuity guarantees subject to fluctuations as a result of interest rate sensitivity?	Yes [] No [)	Χ]		
26.4	If the response to 26.3 is YES, does the reporting entity utiliz		V . T . N . F	,		
		26.41 Special accounting provision of SSAP No. 108	Yes [] No [Yes [] No [J l		
		26.43 Other accounting guidance		j		
26.5		ccounting provisions of SSAP No. 108, the reporting entity attests to the	Yes [] No [1		
	 The reporting entity has obtained explicit approval fr Hedging strategy subject to the special accounting p Actuarial certification has been obtained which indic reserves and provides the impact of the hedging str Financial Officer Certification has been obtained wh 					
27.1	Were any preferred stocks or bonds owned as of December issuer, convertible into equity?	31 of the current year mandatorily convertible into equity, or, at the option of the	Yes [] No [)	Х]		
27.2	If yes, state the amount thereof at December 31 of the currer	nt year.	.\$			
28.	offices, vaults or safety deposit boxes, were all stocks, bonds custodial agreement with a qualified bank or trust company in	eal estate, mortgage loans and investments held physically in the reporting entity's is and other securities, owned throughout the current year held pursuant to a in accordance with Section 1, III - General Examination Considerations, F. Agreements of the NAIC Financial Condition Examiners Handbook?	Yes [X] No [1		
28.01	For agreements that comply with the requirements of the NA	IC Financial Condition Examiners Handbook, complete the following:				
	1	2	1			
	Name of Custodian(s) Key Private Rank	Custodian's Address 4900 Tiedeman Road, Brooklyn, OH 44144-2302				
	US Bank	1555 N. Rivercenter Dr. Suite 300 Milwaukee, WI 53212				

	1 Name(s)		2 Location(s)		3 Complete Explanation(s)			
=	changes, including name mplete information relating	-	odian(s) identified i	n 28.01 during the cu	rrent year?		Yes	[]	No [
	1 ustodian	New	2 Custodian	3 Date of Ch	ange	4 Rea			
make investment deci	ent – Identify all investme sions on behalf of the rep ccess to the investment a	orting entity. For ass	sets that are manag securities"]	ed internally by empl					
	1 Name of Firm or Indi	vidual		2 ation					
Joanne Lauterbach			I						
28.0597 For those firm	ns/individuals listed in the ith a "U") manage more the	table for Question 2	8.05, do any firms/i	ndividuals unaffiliate			Yes	[X]	No
	viduals unaffiliated with the nder management aggre						Yes	[X]	No
For those firms or indithe table below.	viduals listed in the table	for 28.05 with an affi	liation code of "A" (affiliated) or "U" (una	ffiliated), pro	vide the information	for		
1		2		3		4		Inve Mana	igem
Central Registration	Name	e of Firm or Individua	l	Legal Entity Identi		Registered Wi	ith	Agre (IMA	eeme
Depository Number					10.	ffice of the Comptr	allar of		
Not Applicable	Key Private Bank				th	ffice of the Comptr ne Currency			
Not Applicable Does the reporting ent	Key Private Bank tity have any diversified m n (SEC) in the Investmen	nutual funds reported	I in Schedule D, Pa	rt 2 (diversified accor	th	ne Currency			
Not Applicable Does the reporting ent Exchange Commission	Key Private Bank tity have any diversified m n (SEC) in the Investmen	nutual funds reported	I in Schedule D, Pa	rt 2 (diversified accor	th	ne Currency	Yes	[]	No [
Not Applicable Does the reporting ent Exchange Commission If yes, complete the form	Key Private Bank tity have any diversified m n (SEC) in the Investmen	nutual funds reported	I in Schedule D, Pa 140 [Section 5(b)(1)	rt 2 (diversified accord)?	th	ne Currency	Yes	[]	No ed ue
Not Applicable Does the reporting ent Exchange Commission If yes, complete the for 1 CUSIP # 29.2999 - Total	Key Private Bank tity have any diversified m n (SEC) in the Investmen	nutual funds reported t Company Act of 19	l in Schedule D, Pa 140 [Section 5(b)(1) 2 Name of Mutual	rt 2 (diversified accord)?	th	ne Currency	Yes	[] 3 Adjuste	No ed ue
Not Applicable Does the reporting ent Exchange Commission If yes, complete the for 1 CUSIP # 29.2999 - Total	Key Private Bank	nutual funds reported t Company Act of 19	l in Schedule D, Pa 140 [Section 5(b)(1) 2 Name of Mutual	rt 2 (diversified accord)?	th	ne Currency	Book/ Carryi	[] 3 Adjuste	No l

GENERAL INTERROGATORIES

30. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
30.1 Bonds	68,950,865	70,925,403	1,974,538
30.2 Preferred stocks	0		0
30.3 Totals	68,950,865	70,925,403	1,974,538

30.4	Describe the sources or methods utilized in determining the fair values: IDC Fixed Income						
31.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes	s [X]	No []	
31.2	If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes	s[X]	No [1	
31.3	If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:						
32.1 32.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes	s[X]	No []	
33.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities?	Yes	s []	No [[X]	
34.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities?	Yes	s []	No [[X]	
35.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes	s []	No [[X]	
36.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 36.a - 36.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	1 1	No I	χ 1	N/4	1 4	

GENERAL INTERROGATORIES

OTHER

37.1	.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?	146,646

37.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

2
Amount Paid
44,533
, i
-

38.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1	2
Name	Amount Paid
Crowell Moring	9,026,657
	, ,

39.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any? ______\$ _____50,200

39.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1	2
Name	Amount Paid
Government Strategies	
	, i

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 1.2	Does the reporting entity have any direct Medicare Supplement Insurance in forc If yes, indicate premium earned on U.S. business only.			
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance 1.31 Reason for excluding			
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien I	not included in Item (1.2) above	\$	
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.		\$	0
1.6	Individual policies:	Most current three years:	·-	
	·	1.61 Total premium earned	\$	0
		1.62 Total incurred claims		
		1.63 Number of covered lives		
		All years prior to most current three years:		
		1.64 Total premium earned		0
		1.65 Total incurred claims		
		1.66 Number of covered lives		
1.7	Group policies:	Most current three years:		
		1.71 Total premium earned	\$	0
		1.72 Total incurred claims	\$	0
		1.73 Number of covered lives		
		All years prior to most current three years:		
		1.74 Total premium earned		0
		1.75 Total incurred claims		
		1.76 Number of covered lives		
2.	Health Test:			
		1 2		
	2.1 Premium Numerator	Current Year Prior Year		
	2.2 Premium Denominator			
	2.3 Premium Ratio (2.1/2.2)			
	2.4 Reserve Numerator			
	2.5 Reserve Denominator			
	2.6 Reserve Ratio (2.4/2.5)	1.0001.000		
3.2 4.1	If yes, give particulars: Have copies of all agreements stating the period and nature of hospitals', physicials and nature of hospitals', physicials and nature of hospitals', physicials and nature of hospitals', physici	ians', and dentists' care offered to subscribers and	Von [V]	No f 1
	dependents been filed with the appropriate regulatory agency?		Yes [X]	No []
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do thes	e agreements include additional benefits offered?	Yes []	No []
5.1	Does the reporting entity have stop-loss reinsurance?		Yes []	No []
5.2	If no, explain:			
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical		226.000
٥.٠		5.32 Medical Only		
		5.33 Medicare Supplement		
		5.34 Dental & Vision		
		5.35 Other Limited Benefit Plan	\$	
		5.36 Other		
6.	Describe arrangement which the reporting entity may have to protect subscribers hold harmless provisions, conversion privileges with other carriers, agreements agreements:	with providers to continue rendering services, and any other		
7.1	Does the reporting entity set up its claim liability for provider services on a service	e date basis?	Yes [X]	No []
7.2	If no, give details			
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year		
0.4	Does the reporting entity have business subject to accoming on the supply			
9.1	Does the reporting entity have business subject to premium rate guarantees?		168 []	INO [X]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months 9.22 Business with rate guarantees over 36 months	\$\$ \$	

10.1	Does the reporting entity have Incentive Pool, Withh	old or Bonus Arı	rangements in its	provider contracts?	?		Yes [X]	No []
10.2	If yes:		1 1	0.22 Amount actua 0.23 Maximum am	nount payable bonu ally paid for year bo nount payable withh ally paid for year wi	onuses	\$ \$	141,192
11.1	Is the reporting entity organized as:			11.13 An Indivi	al Group/Staff Mod dual Practice Asso Model (combinatio	ciation (IPA), or, .	Yes [] No [X]] No [X]] No [X]
11.2 11.3 11.4 11.5 11.6	Is the reporting entity subject to Statutory Minimum of the state requiring such minifyes, show the amount required	nimum capital ar	nd surplusl				\$	No [] <u>Maine</u> 14,465,520 No [X]
12.	List service areas in which reporting entity is license	d to operate:						
	New Hamps	shire		e Area				
13.1	Do you act as a custodian for health savings accoun	ts?					. Yes []	No [X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$	
13.3	Do you act as an administrator for health savings ac	counts?					. Yes []	No [X]
13.4	If yes, please provide the balance of funds administe	ered as of the rep	porting date				\$	
14.1 14.2	Are any of the captive affiliates reported on Schedul If the answer to 14.1 is yes, please provide the follow		orized reinsurers?	?		Yes [] No [] N/A [X]
	1	2	3	4		Supporting Reserv		
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other	
15.	Provide the following for individual ordinary life insur ceded):	ance* policies (l	J.S. business only	15.1 [15.2]		itten ns	\$ \$	
	Term(whether full und Whole Life (whether f Variable Life (with or Universal Life (with or Variable Universal Life	derwriting, limited ull underwriting, without secondar without second	limited underwriti ry gurarantee) ary gurarantee)	issue, "short form ng, jet issue, "short				
16.	Is the reporting entity licensed or chartered, registered	ed, qualified, elig	ible or writing bus	siness in at least tw	o states?		Yes [X] No	0 []
16.1	If no, does the reporting entity assume reinsurance to domicile of the reporting entity?						Yes [] No	0 []

FIVE-YEAR HISTORICAL DATA

		1 2020	2 2019	3 2018	4 2017	5 2016
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	218,975,407	182,400,876	170,659,367	72,937,723	101,985,131
2.	Total liabilities (Page 3, Line 24)	78,835,404	98,211,955	113,325,811	39,202,929	63,367,838
3.	Statutory minimum capital and surplus requirement	14,465,520	15,932,156	27,545,738	21,959,422	35,433,552
4.	Total capital and surplus (Page 3, Line 33)	140 , 140 , 003	84,188,921	57,333,556	33,734,794	38,617,293
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	243,934,497	242,544,604	380,316,002	266,227,778	377,805,773
6.	Total medical and hospital expenses (Line 18)	137,374,363	158,047,040	283,260,726	227,804,241	375,949,286
7.	Claims adjustment expenses (Line 20)	14,204,753	17,303,461	18,515,638	12,525,535	16,883,743
8.	Total administrative expenses (Line 21)	40,765,985	37,578,208	37,732,988	30,477,588	42,679,506
9.	Net underwriting gain (loss) (Line 24)	55,612,156	23,315,895	25,006,650	(4,579,586)	(14,634,221)
10.	Net investment gain (loss) (Line 27)	1,574,472	3,276,791	1,860,984	309,134	647,774
11.	Total other income (Lines 28 plus 29)	(684, 162)	(1,405,842)	(1,580,815)	(2,075,389)	0
12.	Net income or (loss) (Line 32)	56,502,466	25, 186,844	25,286,819	(6,345,841)	(13,986,447)
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	42,999,018	799,044	99,596,671	(8,792,950)	(54,701,137)
	Risk-Based Capital Analysis					
14.	Total adjusted capital	140,140,003	84, 188,921	57,333,556	33,734,794	38,617,293
15.	Authorized control level risk-based capital	7,238,898	7,966,078	13,772,869	10,979,711	17,716,776
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	26,130	37,062	50,052	37,784	67,539
17.	Total members months (Column 6, Line 7)	337,405	468,819	633,678	498,750	925,926
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)					
20.	Cost containment expenses	4.0	4.5	2.7	2.7	
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					104.0
23.	Total underwriting gain (loss) (Line 24)	22.8	9.6	6.6	(1.7)	(3.9)
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	20,259,444	32,590,939	26,246,949	42,918,948	44,374,373
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	23,237,320	45,498,040	29,226,654	50,354,371	48,902,932
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0				
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0			
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0			
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)		0	0	0	0
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	0
	Total investment in parent included in Lines 26 to					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure			
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?	Yes [] No []
If no, please explain:			

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories


	Allocated by States and Territories										
		I	1	2	3	4	Direct Bus 5	siness Only 6	7	8	9
			Active Status	Accident & Health	3 Medicare	4 Medicaid	Federal Employees Health Benefits Plan	Life & Annuity Premiums & Other	Property/ Casualty	8 Total Columns 2	9 Deposit-Type
	States, etc.		(a)	Premiums	Title XVIII	Title XIX	Premiums	Considerations	Premiums	Through 7	Contracts
1.	Alabama	<i>,</i>	N							0	
2.	Alaska		N	ļ ļ		l	ļ	ļ ļ	l	0	ļ
	Arizona		N	{ }		l	ļ	}	ļ	ļ0	ļ
	Arkansas		NNN	 			ļ ₁	······	ļ	0	ł
5. 6.	California		NNNNN	 			ļ ₋		ł	U	t
7.			NN	[n	
8.	Delaware	DE	N							0	[
	District of Columbia .	DC	N	ļ ļ		<u> </u>	L	ļ ļ	<u> </u>		ļ
	Florida		N	ļ ļ		l	L	ļ ļ	l	0	ļ
11.	Georgia	_	N	ļ			ļ			0	ļ
	Hawaii		N N	 		}	ļ ₋	}	ļ	0	ł
13. 14.	IdahoIllinois		N N I	 			ļ ₁		ļ	0	ł
15.	Indiana		NNNN							0	
16.	lowa		N				ļ	[0	
17.	Kansas	KS	N	<u> </u>			ļ	[[0	L
18.	Kentucky	KY	N	ļ ļ		<u> </u>	L	ļ ļ	<u> </u>	0	ļ
	Louisiana		N			l	ļ	ļ ļ	l	0	ļ
	Maine		L	200,040,163			ļ	ł		200,040,163	ł
21. 22.	Maryland Massachusetts		NNNNNN	 		 	ļ	ţ	!	0	t
	Massachusetts Michigan		NI NI	 		ļ	·····		ł	U	t
23. 24.	Minnesota		NNNNN							n -	
	Mississippi		NN.							0	<u> </u>
26.	Missouri	MO	N	ļ l			ļ	l l		0	L
27.	Montana	MT	N	ļ ļ		<u> </u>	L,	ļ ļ	<u> </u>	0	ļ
28.	Nebraska		N	ļ ļ		l ₁	ļ	ļ ļ	l	0	ļ
	New Hampshire		N	ļ			ļ	······		0	
	New Hampshire New Jersey		L N	 		·····	······	ţ	!	0	ł
	New Jersey New Mexico		N I	 		 	ļ ₋	ļ	ł	U	t
	New York		NNNN							n -	
34.	North Carolina		NN.					[0	[
_	North Dakota	_	N							0	
36.	Ohio	ОН	N	ļ l			ļ	l		0	L
37.	Oklahoma	OK	N	ļ ļ		<u> </u>	L	ļ ļ	<u> </u>	0	ļ
38.	Oregon		N	ļ ļ		l	ļ	ļ ļ	l	0	ļ
	Pennsylvania		N				ļ			0	ļ
40. 41.	Rhode Island South Carolina		N N	 		·····	ļ ₁	}	ļ	0	ł
41. 42.	South Carolina		NNNNNN	†			······		†	0	t
	Tennessee	_	NN.							0	
44.	Texas		NN.							0	<u> </u>
45.	Utah	UT	N	ļ l			ļ	l		0	L
46.	Vermont	VT	N	ļ ļ		<u></u>	L	ļ ļ	<u> </u>	0	ļ
	Virginia		N	ļ ļ		l	ļ	ļ ļ	l	0	ļ
	Washington		N					·····		0	ļ
49. 50.	West Virginia		NN.	 		}	ļ ₁	}	 	0	ł
	Wisconsin Wyoming		N N	 		†	ļ ₋	ļ	ł	0	t
51. 52.	American Samoa		NNNNN						*****	n -	İ
53.	Guam	_	NN.				ļ	[0	
54.	Puerto Rico	PR	N	ļ l		<u> </u>	ļ	<u> </u>		0	L
55.	U.S. Virgin Islands		N	ļ ļ			L			0	ļ
56.	Northern Mariana	N45	N			1	Ι,	<u> </u>	1	_	I
57.	Islands		NNNNNN	 				·····	·····	0	l
57. 58.	Aggregate other		in	†			ļ	ļ	ļ	υ	ļ
	alien		XXX	0	0	0	0	0	0	0	0
59.	Subtotal		XXX	200,040,163	0	0	0	0	0	200,040,163	0
60.	Reporting entity contributions for Em		XXX							0	
61.	Benefit Plans Total (Direct Busines		XXX	200,040,163	0	0	0	0	0	200,040,163	0
- 1.	DETAILS OF WRITE			,070,100	U	· · ·	 		 	_55,040,100	t
58001.			XXX				<u> </u>		l		
58002.			XXX				ļ	ļ			L
58003.			XXX	ļ		<u> </u>	L	ļ	<u> </u>	ļ	ļ
58998.	Summary of remainir write-ins for Line 58 f	from	XXX	0	0	0	0	0	0	0	0
58990	overflow page Totals (Lines 58001 t			T	U	U	ļ	u	ιυ		Ι
	58003 plus 58998)(Li above)		XXX	0	0	0	0	0	0	0	0
a) Active	e Status Counts:	_	od incurance ca				2 P Pogis				

⁽a) Active Status Counts:
L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG...
E - Eligible - Reporting entities eligible or approved to write surplus lines in the state...
N - None of the above - Not allowed to write business in the state... ...20

⁽b) Explanation of basis of allocation by states, premiums by state, etc. Allocation is based on the residency of the member or group

R - Registered - Non-domiciled RRGs...

Q - Qualified - Qualified or accredited reinsurer. ____0



ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Maine Community Health Options OVERFLOW PAGE FOR WRITE-INS

NONE